The effect of dose interval on the survival of L1210 leukemic mice treated with DNA synthesis inhibitors.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003561:Cytarabine / Q000008:administration & dosage; D004273:DNA, Neoplasm / Q000096:biosynthesis; D005561:Formates / Q000008:administration & dosage; D006918:Hydroxyurea / Q000008:administration & dosage; D007939:Leukemia L1210 / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D011725:Pyridines / Q000008:administration & dosage; D013882:Thiosemicarbazones / Q000008:administration & dosage; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D005561:Formates; D011725:Pyridines; D013882:Thiosemicarbazones; D003561:Cytarabine; D013936:Thymidine; D006918:Hydroxyurea; D002166:Camptothecin